Novo Nordisk
NVO
$125.41
Share price
-0.59%
Change (1 day)
47.13%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
P/S ratio for Novo Nordisk (NVO)
P/S ratio as of April 2024 (TTM): 16.6
According to Novo Nordisk's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 16.6453. At the end of 2023 the company had a P/S ratio of 13.6.
P/S ratio history for Novo Nordisk from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 13.6 | 12.21% |
| 2022 | 12.2 | 4.89% |
| 2021 | 11.6 | 40.15% |
| 2020 | 8.27 | 8.61% |
| 2019 | 7.61 | 19.98% |
| 2018 | 6.35 | -16.63% |
| 2017 | 7.61 | 33.98% |
| 2016 | 5.68 | -40.33% |
| 2015 | 9.52 | 31.16% |
| 2014 | 7.26 | 6.83% |
| 2013 | 6.79 | 1.79% |
| 2012 | 6.68 | 22.64% |
| 2011 | 5.44 | -13.47% |
| 2010 | 6.29 | 50.04% |
| 2009 | 4.19 | 17.18% |
| 2008 | 3.58 | -32.99% |
| 2007 | 5.34 | 33.24% |
| 2006 | 4.01 | 21.24% |
| 2005 | 3.31 | -9.26% |
| 2004 | 3.64 | 8.82% |
| 2003 | 3.35 | 16.88% |
| 2002 | 2.86 | -28.15% |
| 2001 | 3.99 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.54 | -84.72% | 🇺🇸 USA |
 Eli Lilly LLY | 20.4 | 22.56% | 🇺🇸 USA |
 Sanofi SNY | 2.31 | -86.12% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 2.20 | -86.78% | 🇺🇸 USA |